HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Tuesday, 11 December 2018

Pharmaceutical pricing regulation in the UK…

…otherwise known as the PPRS, is being reviewed and the initial heads of agreement have been published.  The ‘voluntary scheme for branded medicines pricing and access’ retains many of the features of the previous schemes such as a cap on branded medicine sales and a stipulation relating to the NICE cost-effectiveness threshold (which remains the same).

Differences include a requirement of NHS England to more actively promote access.  Further development of the Innovation Scorecard is highlighted as one approach as well as “committing to the objective of reaching the upper quartile of uptake for 5 highest health gain categories”….which is worrying….highest health gain categories are not necessarily the most cost-effective.

Other aspects of the scheme are less well described, such as exemptions from the scheme…something about 3 years post-licensing freedom of pricing?  We’ll have to wait for further details about this.

Monday, 10 December 2018

Vacancy in HEDS - Research Associate/Research Fellow in Discrete Choice Experiments in Health and Health Care

We have a great opportunity for you to come and join us at Regent Court and ScHARR - details below.

This is an exciting opportunity to work in a multi-disciplinary team on the development of new discrete choice experiments in health and health care. We are looking for someone with a relevant economics, health economics, psychometrics or choice modelling background to work with researchers in the fields of clinical trials and outcome measurement, and who will be involved with the collection and analysis of both quantitative and qualitative data.

The role is based in the Health Economics and Decision Science (HEDS) Section of ScHARR and will involve research funding from a variety of sources, including NIHR and pharmaceutical companies. This includes exciting opportunities to work on projects to develop discrete choice experiments in the areas of pilonidal disease and ulcerative colitis. The role will involve a variety of tasks, including the managing, undertaking and analysing qualitative interviews with patients and clinicians, and data collection and analyses of larger online discrete choice experiment surveys assessing treatment preferences. More generally, you will be involved in: reviewing, interviewing, managing data-collection in questionnaire surveys, and undertaking analyses of discrete choice experiments and contributing to their study design.
Image of Regent Court
Regent Court
You will initially work with Dr Phil Shackley and Dr Donna Rowen on a number of projects, with a view to developing your own programme of work. You will be encouraged to contribute to Masters-level teaching and supervision and should have a Masters Degree or equivalent in a relevant subject, for example, economics or psychology. A PhD in a related subject is desirable (essential for the role of Research Fellow Grade 8). 

This full-time post is fixed-term for 2 years and is available with a immediate start. We’re one of the best not-for-profit organisations to work for in the UK. The University’s Total Reward Package includes a competitive salary, a generous Pension Scheme and annual leave entitlement, as well as access to a range of learning and development courses to support your personal and professional development. We build teams of people from different heritages and lifestyles whose talent and contributions complement each other to greatest effect. We believe diversity in all its forms delivers greater impact through research, teaching and student experience. 

Post title: Research Associate/Research Fellow in Discrete Choice Experiments in Health and Health Care 

Post ref: UOS021058

Closing date: 3.1.2019  

Wednesday, 5 December 2018

Latest publications from HEDS from November

Once again we explore what new publications have been produced by HEDS in collaboration with colleagues in ScHARR. Many of these are currently in press, so you can find much of our work in its open access form via our institutional repository. Tuck in here.

Image of Value in Health journal
Value in Health   
       Aber, A. et al. (2018) Sex differences in national rates of repair of emergency abdominal aortic aneurysm. British Journal of Surgery.

       Alshreef, A. O. et al. (2018) 'Assessing the Appropriateness of Existing Model Adaptation Methods for Low and Middle-Income Countries', in Value in Health. 6 November 2018 Elsevier. 

       Ballinger, R. et al. (2018) Measurement of Utilities Associated with Parenteral Support Requirement in Patients with Short Bowel Syndrome and Intestinal Failure. Clinical Therapeutics. 40 (11), 1878–1893.e1.

Campbell, F., Lawton, J., et al. (n.d.) Follow-Up Support for Effective type 1 Diabetes self-management (The FUSED Model): A systematic review and meta-ethnography of the barriers, facilitators and recommendations for sustaining self-management skills after attending a structured education programme. BMC Health Services Research.

Campbell, F., Weeks, L., et al. (n.d.) 'Rapid Qualitative Reviews - What, Why, How and Where next?', in 25th Cochrane Colloquium Conference Abstracts

Chambers, D., Cantrell, A., et al. (n.d.) Digital and online symptom checkers and health assessment/triage services for urgent care: a systematic review. Health Services and Delivery Research.

Image of Medical Decision Making
Medical Decision Making
Chambers, D., Booth, A., et al. (n.d.) Evidence to support delivery of effective health services: a responsive programme of rapid evidence synthesis. Evidence & Policy.

Dodd, P. J. et al. (2018) Simple Inclusion of Complex Diagnostic Algorithms in Infectious Disease Models for Economic Evaluation. Medical Decision Making. 38 (8), 930–941. [online]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30403578.

Fitzgerald, N. et al. (2018) Exploring the impact of public health teams on alcohol premises licensing in England and Scotland (ExILEnS): procotol for a mixed methods natural experiment evaluation. BMC Medical Research Methodology. 18 (123)

Image of PharmacoEconmics journal
       Lumley, E. et al. (2018) Experiences of living with varicose veins: a systematic review of qualitative research. Journal of Clinical Nursing. [online]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30461103.

       Pennington, B. et al. (2018) Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. [online]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30465228.

       Trauer, J. M. et al. (2018) The Importance of Heterogeneity to the Epidemiology of Tuberculosis. Clinical Infectious Diseases. [online]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30383204.

Monday, 3 December 2018

Join us for our next HTA and Health Economics course webinar - 14th January 12pm UK Time

Want to learn more about studying and online at ScHARR? Then sign up for our free course webinar on 14th Jan 2019 12pm UK time, here
It is a great opportunity to find out more about our courses and how we deliver them.

ScHARR HEDS HTA Course webpage

Friday, 30 November 2018

The EQ-5D-5L tariff for England

The Economic Evaluation Policy Research Unit (EEPRU) was commissioned by the Department of Health and Social Care (DHSC) to undertake a review of the EQ-5D-5L value set for England which was published earlier this year in Health Economics.  The work on the value set was a collaboration between researchers at the University of Sheffield, the Office of Health Economics, and the University of Technology Sydney.

The EEPRU review of the value set has now been published and is critical of several aspects of the EQ-5D-5L work.

The EQ-5D-5L value set for England study team’s response to the criticisms made by EEPRU can be downloaded here, accompanied by a technical appendix.

Given the importance of the EQ-5D-5L’s value set for England, researchers are encouraged to read both sets of documents and make up their own minds.

NICE’s updated position statement on the use of the EQ-5D-5L value set and on mapping EQ-5D-5L data can be found here.

Thursday, 29 November 2018

EUnetHTA Prioritisation List (EPL) for Joint Assessments

From the EUnetHTA website:

“The EPL expresses the identified significant interest of national HTA bodies in relation to individual compounds as presented in the list. By pro-actively selecting those topics in direct collaboration with national bodies, EUnetHTA strives to increase implementation of Joint Assessments qualitatively and quantitatively at the national level. This is one of the key elements of Joint Action 3.

The Heads of HTA Agencies of the countries represented in the EUnetHTA Executive Board (ExB) have agreed to take a more proactive approach in performing Joint Assessments. There is a strong consensus within EUnetHTA that this approach will strengthen the methods and procedures of the pharmaceutical Joint Assessments to increase the benefits of European cooperation on HTA and to shape the future model of collaboration. This facilitates national implementation and uptake of the Joint Assessments, and therefore the EUnetHTA ExB has agreed upon the creation of the EPL.

The EPL is based on the Innovation Observatory. The list was cross-checked with the open access Dutch Horizon Scan and the publicly available EMA list of medicines under evaluation to estimate regulatory timelines. In compiling the list, EUnetHTA partners were asked to indicate their interest, including using the assessment at the national level. The final prioritisation was based on this feedback and combined with the anticipated feasibility of the compatibility of timelines of the EUnetHTA assessment and estimated regulatory timelines. Therefore, prioritisation does not discriminate between pharmaceutical companies, compounds or indication. Of note, the EPL is an ad-hoc approach. As such, it will be evaluated and, in the future, may lead to a systematic approach.

The EPL stands complementary to the already well-established mechanism for voluntary submission of new compounds, both of which will continue in the future to run in parallel to the EPL.

EUnetHTA will interface with all companies on the EPL in order to establish further dialogue and increase cooperation on prioritised topics.”

Tuesday, 27 November 2018

HEDS Short Course - Instant Evidence Based Medicine: How to Quickly Synthesise Research

HEDS Short Course - Instant Evidence Based Medicine: How to Quickly Synthesise Research

1 day course - Tuesday 12th February 2019

OverviewThis course will introduce participants to the concept of research synthesis and explore simple ways to rapidly bring evidence together to inform decision making. During the day we will undertake a search for high quality evidence to answer a clinical question. We will then look at ways of identifying the findings/key themes from the research and present various methods/tools to quickly bring the results together to form a useful overview of the evidence quickly and effectively.
If you are new to research synthesis or need to expand your skill set to include rapid synthesis the this course will be ideal. It will offer an introduction to synthesis for those who do not need to undertake full scale systematic reviews, but would like to be able to bring research findings together simply and quickly to form a clear picture.

Link to our online store, for all ScHARR short course bookings:

If you require further information, please do not hesitate to contact the ScHARR Short Course Unit via this email address.
Mrs Karen Holden
Short Courses & Events Officer
University of Sheffield
Regent Court
30 Regent Street
S1 4DA
Tel:  0114 222 2968
Fax: 0114 272 4095

The early bird booking rate for this course will close 12th December 2018
Standard booking will close 29th January 2019

Monday, 26 November 2018

Website of the Month for November - Trip Search Engine

For November's Website of the Month we have chosen the excellent Trip Search Engine

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care. Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Their motto is ‘Find evidence fast’ and this is something they aim to deliver for every single search.

As well as research evidence they also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

They also include the PICO search tool which allows you to search for research in relation to their four criteria of Population, Intervention, Comparison, Outcome. 

For further information on Trip you can visit their website here

If you have questions please contact Trip via jon.brassey@tripdatabase.com

Image of the Trip Search Engine website

Thursday, 22 November 2018

October’s CEAs, systematic reviews and epidemiological models in LMICs

To help us keep on top of current research in low and middle-income countries, we are running a monthly search of research that is aligned to our core research interests.  It's a simple search strategy, with those published last month that are most aligned to our interests listed below.  The full list of articles is kept in our "Searches archive" in the right-hand column.
  • Campos NG, Lince-Deroche N, Chibwesha CJ, Firnhaber C, Smith JS, Michelow P, et al. Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study. Journal of acquired immune deficiency syndromes (1999). 2018;79(2):195-205.
  • Chan J, Wu Y, Wood J, Muhit M, Mahmood MK, Karim T, et al. Burden of Congenital Rubella Syndrome (CRS) in Bangladesh: Systematic review of existing literature and transmission modelling of sero-prevalence studies. Infectious disorders drug targets. 2018.
  • Fan Q, Ming WK, Yip WY, You JHS. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2018.
  • Gyawali B, Bloch J, Vaidya A, Kallestrup P. Community-based interventions for prevention of Type 2 diabetes in low- and middle-income countries: a systematic review. Health promotion international. 2018.
  • Khan AI, Levin A, Chao DL, DeRoeck D, Dimitrov DT, Khan JAM, et al. The impact and cost-effectiveness of controlling cholera through the use of oral cholera vaccines in urban Bangladesh: A disease modeling and economic analysis. PLoS neglected tropical diseases. 2018;12(10):e0006652.
  • Mandelzweig K, Leligdowicz A, Murthy S, Lalitha R, Fowler RA, Adhikari NKJ. Non-invasive ventilation in children and adults in low- and low-middle income countries: A systematic review and meta-analysis. Journal of critical care. 2018;47:310-9.
  • Sun L, Sadique Z, Dos-Santos-Silva I, Yang L, Legood R. Cost-effectiveness of Breast Cancer Screening Programme for Women in Rural China. International journal of cancer. 2018.
  • Vieira MCA, Nery JS, Paixao ES, Freitas de Andrade KV, Oliveira Penna G, Teixeira MG. Leprosy in children under 15 years of age in Brazil: A systematic review of the literature. PLoS neglected tropical diseases. 2018;12(10):e0006788.

Wednesday, 21 November 2018

NHS England consultations…

…on several Specialised Services clinical commissioning policies are open.  These proposals are based on a ‘rapid HTA process’ which was parly informed by work in HEDS.  The policies are:
  • Clinical commissioning policies consultation for: Bendamustine for relapsed multiple myeloma (all ages)
  • Clinical Commissioning Policy Proposition: 18F-flourodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) as part of radical radiotherapy treatment planning for oesophageal cancer (all ages)

More details here.